Protosappanin A (PTA),是一种免疫制剂,是从Caesalpinia sappanL 中分离得到的一种主要联苯化合物,通过下调JAK2和STAT3的磷酸化,抑制JAK2/STAT3依赖的炎症通路。
生物活性 | Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated fromCaesalpinia sappanL, suppressesJAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation ofJAK2andSTAT3[1]. |
IC50& Target[1] | |
体外研究 (In Vitro) | Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) significantly inhibits the production of TNF-α and IL-1β in LPS-activated BV2 microglia. And the mRNA expressions of IL-6, IL-1β, and MCP-1 are reduced by PTA in a dose-dependent manner in BV2 microglial cell line[1]. Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3, as well as STAT3 nuclear translocation against LPS treatment[1]. Protosappanin A (PTA: 12.5, 25, 50 μM, 24 hours) shows obvious effect on disturbing the interaction of transmembrane protein CD14 with Toll-like receptor-4, resulting in the inhibition of NF-κB-dependent oxidative and nitrative stress in LPS-induced BV2 microglia[2].
Western Blot Analysis[1] Cell Line: | Murine BV2 microglial cell line. | Concentration: | 12.5, 25, 50 μM. | Incubation Time: | 24 hours. | Result: | Inhibits the releases of NO, TNF-α and IL-1β in LPS-induced BV2 cells. Attenuated IL-6, IL-1β and MCP-1 gene expressions in the LPS-induced BV2 cells. Suppressed JAK2/STAT3 pathway activation in the LPS-induced BV2 cells.
|
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Leguminosae
- Caesalpinia sappanL.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
溶解性数据 | In Vitro: DMSO : 250 mg/mL(918.27 mM;Need ultrasonic) 配制储备液 1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL | 5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL | 10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (7.64 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (7.64 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (7.64 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (7.64 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (7.64 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (7.64 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|